$INCY
INCYTE CORP Stock $incy

$incy Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000110465912073204 Filed on November 01, 2012

Income Statement

Concept	2012 Q3	2011 Q4	2011 Q3
Revenue	$60.49M	$28.89M	$16.78M
YoY Change	260.46%	-66.37%	-0.7%
Cost Of Revenue	$31.00K		$0.00
YoY Change
Gross Profit	$60.46M		$16.80M
YoY Change	259.89%
Gross Profit Margin	99.95%		100.11%
Selling, General & Admin	$20.52M	$21.20M	$14.28M
YoY Change	43.68%	96.3%	68.02%
% of Gross Profit	33.94%		85.01%
Research & Development	$50.08M	$51.90M	$44.60M
YoY Change	12.27%	58.23%	45.76%
% of Gross Profit	82.83%		265.5%
Depreciation & Amortization	$7.600M	$7.100M	$6.800M
YoY Change	11.76%	4.41%	25.93%
% of Gross Profit	12.57%		40.48%
Operating Expenses	$70.60M	$73.00M	$58.89M
YoY Change	19.89%	67.43%	50.99%
Operating Profit	-$10.14M		-$42.10M
YoY Change	-75.92%
Interest Expense	$11.57M	-$10.90M	$11.02M
YoY Change	5.03%	11.22%	-206.98%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$21.68M	-$55.10M	-$53.08M
YoY Change	-59.15%	-269.54%	63.82%
Income Tax	$26.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$21.70M	-$55.10M	-$53.10M
YoY Change	-59.13%	-269.54%	67.51%
Net Earnings / Revenue	-35.87%	-190.73%	-316.41%
Basic Earnings Per Share	-$0.17
Diluted Earnings Per Share	-$0.17	-$435.9K	-$420.4K
COMMON SHARES
Basic Shares Outstanding	130.9M shares
Diluted Shares Outstanding	130.9M shares

Balance Sheet

Concept	2012 Q3	2011 Q4	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$243.6M	$277.6M	$317.0M
YoY Change	-23.15%	-34.56%	-19.87%
Cash & Equivalents	$239.1M	$273.2M	$312.3M
Short-Term Investments	$4.500M	$4.400M	$4.600M
Other Short-Term Assets	$18.40M	$26.80M	$27.00M
YoY Change	-31.85%	4.69%	21.62%
Inventory	$190.0K	$0.00
Prepaid Expenses
Receivables	$16.50M	$6.400M	$2.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$278.7M	$310.8M	$346.4M
YoY Change	-19.54%	-31.77%	-18.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.169M	$6.431M	$6.100M
YoY Change	1.13%	33.87%	154.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.000M	$3.500M	$10.00M
YoY Change	-50.0%	-66.45%	-64.79%
Total Long-Term Assets	$17.81M	$18.18M	$24.80M
YoY Change	-28.2%	-46.72%	-41.09%
TOTAL ASSETS
Total Short-Term Assets	$278.7M	$310.8M	$346.4M
Total Long-Term Assets	$17.81M	$18.18M	$24.80M
Total Assets	$296.5M	$329.0M	$371.2M
YoY Change	-20.11%	-32.81%	-20.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.76M	$14.94M	$11.00M
YoY Change	16.04%	38.67%	41.03%
Accrued Expenses	$22.75M	$24.77M	$42.90M
YoY Change	-46.97%	57.72%	0.23%
Deferred Revenue
YoY Change
Short-Term Debt	$9.800M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$137.6M	$135.6M	$121.0M
YoY Change	13.75%	19.41%	2.98%
LONG-TERM LIABILITIES
Long-Term Debt	$324.8M	$316.2M	$310.3M
YoY Change	4.67%	7.77%	7.71%
Other Long-Term Liabilities	$54.10M	$104.3M	$121.0M
YoY Change	-55.29%	-39.08%	-35.64%
Total Long-Term Liabilities	$378.9M	$420.5M	$431.3M
YoY Change	-12.15%	-9.49%	-9.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$137.6M	$135.6M	$121.0M
Total Long-Term Liabilities	$378.9M	$420.5M	$431.3M
Total Liabilities	$516.5M	$556.0M	$552.2M
YoY Change	-6.47%	-3.84%	-6.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.673B	-$1.610B
YoY Change		13.11%
Common Stock	$1.451B	$1.381B
YoY Change		3.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$220.0M	-$227.1M	-$181.0M
YoY Change
Total Liabilities & Shareholders Equity	$296.5M	$329.0M	$371.2M
YoY Change	-20.11%	-32.81%	-20.1%

Cashflow Statement

Concept	2012 Q3	2011 Q4	2011 Q3
OPERATING ACTIVITIES
Net Income	-$21.70M	-$55.10M	-$53.10M
YoY Change	-59.13%	-269.54%	67.51%
Depreciation, Depletion And Amortization	$7.600M	$7.100M	$6.800M
YoY Change	11.76%	4.41%	25.93%
Cash From Operating Activities	-$27.10M	-$39.80M	-$46.90M
YoY Change	-42.22%	-245.26%	58.45%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$1.000M	-$1.200M
YoY Change	-66.67%	-62.96%	140.0%
Acquisitions
YoY Change
Other Investing Activities	$100.0K	-$100.0K	$300.0K
YoY Change	-66.67%	-111.11%	-76.92%
Cash From Investing Activities	-$300.0K	-$1.100M	-$900.0K
YoY Change	-66.67%	-38.89%	-212.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.900M	1.800M	1.100M
YoY Change	709.09%	-48.57%	-67.65%
NET CHANGE
Cash From Operating Activities	-27.10M	-39.80M	-46.90M
Cash From Investing Activities	-300.0K	-1.100M	-900.0K
Cash From Financing Activities	8.900M	1.800M	1.100M
Net Change In Cash	-18.50M	-39.10M	-46.70M
YoY Change	-60.39%	-234.36%	83.86%
FREE CASH FLOW
Cash From Operating Activities	-$27.10M	-$39.80M	-$46.90M
Capital Expenditures	-$400.0K	-$1.000M	-$1.200M
Free Cash Flow	-$26.70M	-$38.80M	-$45.70M
YoY Change	-41.58%	-228.9%	57.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	incy	Deferred Collaborative Agreements Revenue Current DeferredCollaborativeAgreementsRevenueCurrent	66973000	USD
CY2012Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	315874000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0000879169
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273164000	USD
CY2011Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4430000	USD
CY2011Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	6415000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7475000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	310778000	USD
	dei	Document Type DocumentType	10-Q
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	137641000	USD
	dei	Entity Registrant Name EntityRegistrantName	INCYTE CORP
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-219950000	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	296535000	USD
CY2012Q3	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	8909000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21500000	USD
CY2011Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	3536000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6431000	USD
CY2011Q4	incy	Intangible And Other Assets Net IntangibleAndOtherAssetsNet	8217000	USD
CY2011Q4	us-gaap	Assets Assets	328962000	USD
CY2012Q3	us-gaap	Assets Assets	296535000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14939000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21856000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	249000	USD
	us-gaap	Interest Expense InterestExpense	32666000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-131461000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-131461000	USD
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4750000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24766000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2332000	USD
CY2011Q4	incy	Deferred Collaborative Agreements Revenue Current DeferredCollaborativeAgreementsRevenueCurrent	66971000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	135614000	USD
CY2011Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	298193000	USD
CY2011Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	17960000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	556039000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	516485000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	126000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1380725000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1642000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1609570000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-227077000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	328962000	USD
CY2011Q3	us-gaap	Contracts Revenue ContractsRevenue	16737000	USD
CY2011Q3	us-gaap	Revenues Revenues	16782000	USD
	us-gaap	Contracts Revenue ContractsRevenue	65211000	USD
CY2012Q3	us-gaap	Interest Payable Current InterestPayableCurrent	9500000	USD
	us-gaap	Revenues Revenues	65565000	USD
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44604000	USD
CY2011Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14282000	USD
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	58886000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42104000	USD
CY2011Q3	us-gaap	Investment Income Net InvestmentIncomeNet	45000	USD
CY2011Q3	us-gaap	Interest Expense InterestExpense	11019000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	126830000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37067000	USD
	us-gaap	Other General Expense OtherGeneralExpense	712000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	164609000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-99044000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21710000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21684000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10138000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	70630000	USD
CY2012Q3	us-gaap	Revenues Revenues	60492000	USD
	us-gaap	Revenues Revenues	183213000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	212319000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29106000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-63006000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-63099000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53078000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-130000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-130000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-165000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-165000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53208000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-131626000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	429000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	507000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21281000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62592000	USD
	us-gaap	Restructuring Costs RestructuringCosts	20000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19948000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21536000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3239000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7628000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	265000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7099000	USD
	incy	Increase Decrease Deferred Revenue Collaborative Agreements IncreaseDecreaseDeferredRevenueCollaborativeAgreements	-50210000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-121936000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.     Organization and business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Incyte Corporation (“Incyte,” “we,” “us,” or “our”) is a biopharmaceutical company focused on developing and commercializing proprietary small molecule drugs for oncology and inflammation. Our pipeline includes compounds in various stages, ranging from preclinical to commercialized product.  Our most advanced compound, JAKAFI</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"> ®</font><font style="FONT-SIZE: 10pt" size="2"> (ruxolitinib), has been approved by the U.S. Food and Drug Administration (“FDA”) as a treatment for patients with intermediate or high-risk myelofibrosis.</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table>
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2807000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1362000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	17714000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17714000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-105584000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417912000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	312328000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-34081000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40229000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1488000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-72822000	USD
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131113577	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131113577	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126471999	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126471999	shares
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	incy	Percentage Of Medi Care Part D Insurance Coverage Gap Required To Be Funded By Manufacturers PercentageOfMediCarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers	0.50	pure
CY2012Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2697000	USD
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3343000	USD
CY2012Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1819000	USD
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1087000	USD
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4430000	USD
CY2012Q3	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4516000	USD
CY2012Q3	incy	Inventory Work In Process Raw Materials And Finished Goods Net Of Reserves InventoryWorkInProcessRawMaterialsAndFinishedGoodsNetOfReserves	5200000	USD
CY2012Q3	us-gaap	Inventory Net InventoryNet	190000	USD
CY2012Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	5018000	USD
CY2011Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	3500000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29400000	USD
CY2011Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7400000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Black-Scholes valuation model
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	70236979	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	70626978	shares
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	131207611	shares
CY2012Q3	us-gaap	Convertible Subordinated Debt Current ConvertibleSubordinatedDebtCurrent	9816000	USD
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	43695000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	92700000	USD
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	31000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	58000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1672000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2332000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239083000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-53078000	USD
CY2011Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	19294000	USD
CY2011Q4	incy	Deferred Collaborative Agreements Revenue Noncurrent DeferredCollaborativeAgreementsRevenueNoncurrent	104272000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	1445000	USD
CY2012Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4516000	USD
CY2012Q3	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	9500000	USD
CY2012Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	16540000	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8899000	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	278728000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6169000	USD
CY2012Q3	incy	Intangible And Other Assets Net IntangibleAndOtherAssetsNet	6620000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	12764000	USD
CY2012Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15839000	USD
CY2012Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22749000	USD
CY2012Q3	incy	Deferred Collaborative Agreements Revenue Noncurrent DeferredCollaborativeAgreementsRevenueNoncurrent	54061000	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	131000	USD
CY2012Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1450439000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2149000	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1672669000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	16737000	USD
	us-gaap	Contracts Revenue ContractsRevenue	90211000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150627000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50079000	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20520000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61634000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	27000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	393000	USD
	us-gaap	Interest Expense InterestExpense	34293000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	11573000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	429000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	507000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22214000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29426000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10125000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8370000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2175000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3220000	USD
	incy	Increase Decrease Deferred Revenue Collaborative Agreements IncreaseDecreaseDeferredRevenueCollaborativeAgreements	-50209000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1909000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	421000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	40229000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26000	USD
	incy	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129093000	shares

Files In Submission

Name	View Source	Status
0001104659-12-073204-index-headers.html	Edgar Link	pending
0001104659-12-073204-index.html	Edgar Link	pending
0001104659-12-073204.txt	Edgar Link	pending
0001104659-12-073204-xbrl.zip	Edgar Link	pending
a12-19883_110q.htm	Edgar Link	pending
a12-19883_1ex31d1.htm	Edgar Link	pending
a12-19883_1ex31d2.htm	Edgar Link	pending
a12-19883_1ex32d1.htm	Edgar Link	pending
a12-19883_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
incy-20120930.xml	Edgar Link	completed
incy-20120930.xsd	Edgar Link	pending
incy-20120930_cal.xml	Edgar Link	unprocessable
incy-20120930_def.xml	Edgar Link	unprocessable
incy-20120930_lab.xml	Edgar Link	unprocessable
incy-20120930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INCY
INCYTE CORP Stock $incy

2012 Q3 Form 10-Q Financial Statement

#000110465912073204 Filed on November 01, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INCY INCYTE CORP Stock $incy

2012 Q3 Form 10-Q Financial Statement

#000110465912073204 Filed on November 01, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INCY
INCYTE CORP Stock $incy